A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to generate protective antibodies, which are then passed to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the point of delivery, precisely when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent coverage when vaccinated four weeks before birth
- Maternal antibodies transferred through the placenta protect newborns from birth
- Protection possible with 2-week gap before early delivery
- Vaccination during third trimester still offers meaningful infant protection
Compelling evidence from recent research
The effectiveness of the RSV vaccine administered during pregnancy has been established through a comprehensive study conducted across England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that six-month timeframe, providing comprehensive and reliable data of the vaccine’s real-world impact. The study’s results have been validated by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The scale of this research gives healthcare professionals and expectant parents with trust in the vaccine’s established performance across different groups and contexts.
The results present a compelling picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This stark contrast underscores the vaccine’s vital importance in preventing serious illness in newborns. The decrease in hospital admissions exceeding 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection levels and hospitalisations. The sizeable sample and thorough nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than isolated cases or limited subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology captured real-world outcomes rather than experimental conditions, providing practical evidence of how the vaccine works when administered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and its hazards
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during peak seasons.
The infection produces deep inflammation in the lungs and airways, making it perilously hard for vulnerable newborns to feed and breathe effectively. Parents commonly see their babies struggling visibly, their chests rising whilst they work to get adequate oxygen into their weakened respiratory system. Whilst the majority of babies recover with clinical support, a small but significant proportion perish from RSV-related complications each year, making prevention through vaccination a critical public health objective for safeguarding the youngest and most at-risk individuals in the population.
- RSV causes lung inflammation, resulting in severe breathing difficulties in infants
- Half of all infants catch the virus during their first few months alive
- Symptoms vary between minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
- More than 20,000 UK infants require serious hospital care for RSV annually
- A small number of babies succumb to RSV complications each year in the UK
Uptake rates and expert recommendations
Since the RSV vaccine programme launched in 2024, health officials have highlighted the importance of pregnant women getting their jab at the optimal time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing matters greatly for guaranteeing newborns benefit from the strongest possible immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery provides approximately 85% protection, experts recommend women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies passed to their babies via the placenta.
The messaging from public health bodies stays clear: pregnant women should prioritise vaccination during their final three months, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those delivering slightly early. This flexible approach recognises the practical demands of pregnancy whilst maintaining strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.
Regional variations in vaccine uptake
Whilst the RSV vaccine programme has been launched across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others remain focused to boost understanding and access to the jab. These geographical variations demonstrate differences across medical facilities, engagement approaches, and community involvement initiatives, though the overall statistics shows consistently strong protection regardless of geographical location.
- NHS trusts launching diverse outreach initiatives to engage with pregnant women
- Regional disparities in vaccine uptake rates in different parts of England require targeted improvement
- Community health services tailoring initiatives to suit specific population needs
Real-world impact and parent viewpoints
The vaccine’s impressive effectiveness provides tangible benefits for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the launch of this protective measure, the 80% drop in admissions represents thousands of infants shielded from critical disease. Parents no more face the troubling prospect of seeing their babies labour to breathe or struggle to eat, symptoms that define severe RSV infections. The vaccine has substantially transformed the landscape of neonatal breathing health, providing expectant mothers a preventative option to protect their most at-risk babies during those vital initial period.
For families like that of Malachi, whose acute RSV infection caused severe brain damage, the vaccine’s availability carries profound emotional significance. His mother’s support of the jab underscores the life-altering consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to women in pregnancy navigating their final trimester, changing what was once an unavoidable seasonal threat into a manageable risk.